

# **Product** Data Sheet

Inhibitors

**Screening Libraries** 

**Proteins** 

# HDAC6-IN-3

Cat. No.: HY-145259 CAS No.: 3023019-99-7 Molecular Formula:  $C_{19}H_{27}N_3O_3$ 

Molecular Weight: 345.44

Target: HDAC; Histone Demethylase

Pathway: Cell Cycle/DNA Damage; Epigenetics

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

### **BIOLOGICAL ACTIVITY**

Description HDAC6-IN-3 (Compound 14), an antiprostate cancer agent, is a potent, orally active HDAC6 inhibitor with IC<sub>50</sub>s ranging from  $0.02-1.54~\mu\text{M for HDAC1/2/3/6/8/10. HDAC6-IN-3} \text{ is also an effective MAO-A (IC}_{50}=0.79~\mu\text{M}) \text{ and LSD1 inhibitor}^{[1]}. \text{ HDAC6-IN-3} \text{ is also an effective MAO-A (IC}_{50}=0.79~\mu\text{M}) \text{ and LSD1 inhibitor}^{[1]}. \text{ HDAC6-IN-3} \text{ is also an effective MAO-A (IC}_{50}=0.79~\mu\text{M}) \text{ and LSD1 inhibitor}^{[1]}. \text{ HDAC6-IN-3} \text{ is also an effective MAO-A (IC}_{50}=0.79~\mu\text{M}) \text{ and LSD1 inhibitor}^{[1]}. \text{ HDAC6-IN-3} \text{ is also an effective MAO-A (IC}_{50}=0.79~\mu\text{M}) \text{ and LSD1 inhibitor}^{[1]}. \text{ HDAC6-IN-3} \text{ is also an effective MAO-A (IC}_{50}=0.79~\mu\text{M}) \text{ and LSD1 inhibitor}^{[1]}. \text{ HDAC6-IN-3} \text{ is also an effective MAO-A (IC}_{50}=0.79~\mu\text{M}) \text{ and LSD1 inhibitor}^{[1]}. \text{ HDAC6-IN-3} \text{ is also an effective MAO-A (IC}_{50}=0.79~\mu\text{M}) \text{ and LSD1 inhibitor}^{[1]}. \text{ HDAC6-IN-3} \text{ is also an effective MAO-A (IC}_{50}=0.79~\mu\text{M}) \text{ and LSD1 inhibitor}^{[1]}. \text{ HDAC6-IN-3} \text{ is also an effective MAO-A (IC}_{50}=0.79~\mu\text{M}) \text{ and LSD1 inhibitor}^{[1]}. \text{ HDAC6-IN-3} \text{ is also an effective MAO-A (IC}_{50}=0.79~\mu\text{M}) \text{ and LSD1 inhibitor}^{[1]}. \text{ HDAC6-IN-3} \text{ is also an effective MAO-A (IC}_{50}=0.79~\mu\text{M}) \text{ and LSD1 inhibitor}^{[1]}. \text{ HDAC6-IN-3} \text{ is also an effective MAO-A (IC}_{50}=0.79~\mu\text{M}) \text{ and LSD1 inhibitor}^{[1]}. \text{ HDAC6-IN-3} \text{ is also an effective MAO-A (IC}_{50}=0.79~\mu\text{M}) \text{ and LSD1 inhibitor}^{[1]}. \text{ HDAC6-IN-3} \text{ is also an effective MAO-A (IC}_{50}=0.79~\mu\text{M}) \text{ and LSD1 inhibitor}^{[1]}. \text{ HDAC6-IN-3} \text{ is also an effective MAO-A (IC}_{50}=0.79~\mu\text{M}) \text{ and LSD1 inhibitor}^{[1]}. \text{ HDAC6-IN-3} \text{ is also an effective MAO-A (IC}_{50}=0.79~\mu\text{M}) \text{ and LSD1 inhibitor}^{[1]}. \text{ HDAC6-IN-3} \text{ is also an effective MAO-A (IC}_{50}=0.79~\mu\text{M}) \text{ and LSD1 inhibitor}^{[1]}. \text{ HDAC6-IN-3} \text{ is also an effective MAO-A (IC}_{50}=0.79~\mu\text{M}) \text{ and LSD1 inhibitor}^{[1]}. \text{ HDAC6-IN-3} \text{ is also an effective MAO-A (IC}_{50}=0.79~\mu\text{M}) \text{ and LSD1 inhibitor}^{[1]}. \text{ HDAC6-IN-3} \text{ is also an effective MAO-A (IC}_{50}=0.79~\mu\text{M}) \text{$ is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition

(CuAAc) with molecules containing Azide groups.

IC<sub>50</sub> & Target KDM1/LSD1

## **REFERENCES**

[1]. Ojha R, et al. Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent. J Med Chem. 2021;64(24):17824-17845.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA